Skip to content

Crescent Biopharma, Inc.

CBIO

CIK 0001253689

← back to feed
Revenue (TTM)
$10.84M
Q1 Apr 2026
Net Income (TTM)
−$92.98M
−761.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.49
−1.7% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-791.8%
Q1 Apr 2026
Net Margin
-857.4%
Q1 Apr 2026
Free Cash Flow (TTM)
−$42.06M
Q1 Apr 2026
Cash
$189.16M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
27.57M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings